Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters Thursday morning.
Hudson also said that the French pharma is not expecting a significant impact from the US legislation targeting Chinese service providers given the “grandfather nature” of existing relationships.
Sanofi, which is making moves to be an “immunology powerhouse,” has made clear over the past few months that it’s looking to narrow its oncology work after several bold platform plays didn’t work out the way it had hoped. Those changes took shape in recent weeks with the planned divestment of Amunix, shuttering of Kiadis and shrinking of a deal with IGM. It’s also led to job cuts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.